Analysts Anticipate Fulgent Genetics Inc (FLGT) to Post ($0.05) EPS

Fulgent Genetics Inc (NASDAQ:FLGT) has been given a consensus broker rating score of 3.00 (Hold) from the two brokers that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a hold rating. Fulgent Genetics’ rating score has declined by 50% in the last 90 days as a result of various analysts’ upgrades and downgrades.

Brokerages have set a 1-year consensus price target of $4.35 for the company and are anticipating that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also given Fulgent Genetics an industry rank of 187 out of 265 based on the ratings given to related companies.

FLGT has been the subject of a number of recent analyst reports. Credit Suisse Group dropped their price objective on Fulgent Genetics from $6.50 to $6.00 and set an “outperform” rating for the company in a report on Thursday, March 1st. Zacks Investment Research upgraded Fulgent Genetics from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, Piper Jaffray Companies cut Fulgent Genetics from an “overweight” rating to a “neutral” rating in a report on Thursday, March 1st.

Several institutional investors and hedge funds have recently added to or reduced their stakes in FLGT. Granahan Investment Management Inc. MA increased its position in Fulgent Genetics by 145.5% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 238,232 shares of the company’s stock valued at $1,141,000 after buying an additional 141,182 shares in the last quarter. Mutual Advisors LLC acquired a new position in Fulgent Genetics during the 4th quarter valued at about $1,662,000. Royce & Associates LP acquired a new position in Fulgent Genetics during the 4th quarter valued at about $219,000. Finally, Thompson Davis & CO. Inc. acquired a new position in Fulgent Genetics during the 4th quarter valued at about $154,000. 7.94% of the stock is owned by hedge funds and other institutional investors.

Fulgent Genetics (NASDAQ:FLGT) traded up $0.03 during trading hours on Wednesday, reaching $3.85. The company’s stock had a trading volume of 1,987 shares, compared to its average volume of 13,188. The company has a market cap of $68.53 and a P/E ratio of -25.67. Fulgent Genetics has a 1-year low of $2.72 and a 1-year high of $11.80.

ILLEGAL ACTIVITY WARNING: This report was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at

Fulgent Genetics Company Profile

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Get a free copy of the Zacks research report on Fulgent Genetics (FLGT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with's FREE daily email newsletter.

Leave a Reply